Alector (ALEC) Projected to Post Quarterly Earnings on Wednesday

Alector (NASDAQ:ALEC - Get Free Report) is anticipated to issue its Q1 2025 quarterly earnings data before the market opens on Wednesday, May 14th. Analysts expect Alector to post earnings of ($0.46) per share and revenue of $4.25 million for the quarter. Alector has set its FY 2025 guidance at EPS.

Alector (NASDAQ:ALEC - Get Free Report) last posted its quarterly earnings data on Wednesday, February 26th. The company reported ($0.02) earnings per share for the quarter, topping the consensus estimate of ($0.61) by $0.59. Alector had a negative return on equity of 108.77% and a negative net margin of 257.54%. The business had revenue of $54.24 million for the quarter, compared to analysts' expectations of $20.41 million. On average, analysts expect Alector to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Alector Stock Up 6.4%

Alector stock traded up $0.08 during trading on Monday, hitting $1.25. The stock had a trading volume of 640,888 shares, compared to its average volume of 815,815. The stock has a market cap of $124.49 million, a price-to-earnings ratio of -0.73 and a beta of 0.76. The stock's 50 day moving average is $1.19 and its two-hundred day moving average is $2.08. Alector has a 1 year low of $0.87 and a 1 year high of $6.78.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on ALEC. Morgan Stanley reissued an "underweight" rating and set a $1.50 target price (down previously from $3.00) on shares of Alector in a report on Friday, March 7th. HC Wainwright boosted their price objective on shares of Alector from $7.00 to $10.00 and gave the stock a "buy" rating in a report on Friday. Two investment analysts have rated the stock with a sell rating, two have assigned a hold rating and three have issued a buy rating to the company's stock. According to MarketBeat.com, the stock presently has a consensus rating of "Hold" and a consensus target price of $4.00.

About Alector

Alector, Inc, a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, an immune activity in the brain with genetic links to multiple neurodegenerative disorders, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases.